Capecitabine
Mostrando 1-11 de 11 artigos, teses e dissertações.
-
1. Capecitabine-induced Subacute Cutaneous Lupus Erythematosus
An. Bras. Dermatol.. Publicado em: 09/12/2019
-
2. Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer
Our objective was to investigate the efficacy and safety of capecitabine maintenance therapy (CMT) after capecitabine-based combination chemotherapy in patients with metastatic breast cancer. The clinical data of 139 metastatic breast cancer patients treated from March 2008 to May 2012 with capecitabine-based combination chemotherapy were retrospectively ana
Braz J Med Biol Res. Publicado em: 25/11/2013
-
3. ANÁLISE DO CUSTO DE MEDICAMENTOS QUIMIOTERÁPICOS, POR MEIO DE MODELOS ARIMA - ARCH / ANALYSIS OF THE COST OF CHEMOTHERAPEUTIC DRUGS BY MEANS OF ARIMA MODELS - ARCH
Atualmente os tratamentos médicos estão cada vez mais caros, em vista disso planejar e controlar custos são mecanismos que podem garantir a sobrevivência das instituições hospitalares. O presente estudo analisou o custo com medicamentos de relevância financeira, entre janeiro de 2003 e novembro de 2010, no Hospital Universitário de Santa Maria. Como
IBICT - Instituto Brasileiro de Informação em Ciência e Tecnologia. Publicado em: 15/08/2011
-
4. A multicenter phase II study of the combination of oxaliplatin, irinotecan and capecitabine in the first-line treatment of metastatic colorectal cancer
The triple drug combination consisting of irinotecan, oxaliplatin and 5-fluorouracil (FOLFOXIRI) has demonstrated higher activity and efficacy compared to the doublet FOLFIRI. 5-Fluorouracil could be substituted in FOLFOXIRI regimen by capecitabine, an oral fluoropyrimidine with similar efficacy. Recently, a dose-finding trial has demonstrated the feasibilit
Nature Publishing Group.
-
5. Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study
A total of 50 patients with advanced pancreatic cancer were enrolled in a phase II study of bevacizumab 15 mg kg−1, capecitabine 1300 mg m−2 daily for 2 weeks and gemcitabine 1000 mg m−2 weekly 2 times; cycles were repeated every 21 days. Radiological response rate was 22%; progression-free survival and over survival were 5.8 and 9.8 months
Nature Publishing Group.
-
6. Recent translational research: antiangiogenic therapy for breast cancer – where do we stand?
The central importance of angiogenesis and our understanding of how new blood vessels are formed have led to the development of novel antiangiogenic therapies. Although the number of agents in development has grown exponentially, only one phase III trial in breast cancer has been completed. In that study the addition of bevacizumab to capecitabine did not ex
BioMed Central.
-
7. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)
Nature Publishing Group.
-
8. All-oral combination of oral vinorelbine and capecitabine as first-line chemotherapy in HER2-negative metastatic breast cancer: an International Phase II Trial
Nature Publishing Group.
-
9. Phase II Study of Bevacizumab With Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411
American Society of Clinical Oncology.
-
10. Capecitabine in combination with irinotecan (XELIRI), administered as a 2-weekly schedule, as first-line chemotherapy for patients with metastatic colorectal cancer: a phase II study of the Spanish GOTI group
Nature Publishing Group.
-
11. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma
Preoperative cisplatin/fluorouracil is used for the treatment of localised oesophageal carcinoma. This phase II study aimed to assess the efficacy and safety of administering preoperative epirubicin/cisplatin/capecitabine (ECX). Patients with stage II or III oesophageal/gastro-oesophageal junctional adenocarcinoma from one institution received 4 cycles of EC
Nature Publishing Group.